Paraben free, dye free & fragrance free
The recommendations are non-binding
In a 2001 study published in Endocrinology , Heffernan and colleagues reported that chronic AOD-9604 administration reduced body weight gain, decreased adipose tissue mass, and increased fat oxidation in obese mice without altering IGF-1 levels or glucose metabolism effects that were abolished in beta3 adrenergic receptor (3-AR) knockout mice, implicating 3-AR signaling as the mechanism of action [1]
In a phase 2 clinical study, patients who were administered 20 mg/day lorcaserin attained an average weight loss of 3.6 kg, which was significantly greater than the average weight loss of 0.3 kg in the placebo group [82]
AOD9604 interacts selectively with metabolic pathways associated with the C-terminal domain, making it a more targeted research tool for lipolytic pathway studies without the confounding variables of full hGH activity
Clinical trial safety data: In the Phase 2 trial, adverse events were comparable to placebo